Loading
NASDAQTechnologySoftware - Infrastructure
Latest quote
$11.68
+$0.27 · +2.37%
Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
Previous close
$11.68
+$0.27 · +2.37%
Regular session · ET · Market data may be delayed.
Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
Day range
Current $11.68
52-week range
Current $11.68
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
58
Mixed
Risk
88
Extreme Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
Day range
Current $11.68
52-week range
Current $11.68
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 125.28K USD | 1.62M USD | 1.63M USD | 1.51M USD | 1.42M USD |
| Cost of goods sold | 72.62K USD | 826.14K USD | 609.21K USD | 505.11K USD | 487.02K USD |
| Gross profit | 52.66K USD | 797.68K USD | 1.02M USD | 1M USD | 933.66K USD |
| Research and development | 2.15M USD | 25.99K USD | 122.31K USD | 320.32K USD | 315.85K USD |
| Selling, general, and administrative | 26.33M USD | 8.89M USD | 9.06M USD | 12.47M USD | 11.71M USD |
| Operating expenses | 28.48M USD | 11.74M USD | 13.14M USD | 27.03M USD | 21.36M USD |
| Interest expense | — | — | — | 10.65M USD | — |
| Depreciation and amortization | 688.58K USD | 695.66K USD | 739.32K USD | 1.31M USD | 1.34M USD |
| Operating income | −28.43M USD | −10.94M USD | −12.12M USD | −26.03M USD | −20.43M USD |
| Net income | −233.1M USD | −12.2M USD | −13.98M USD | −25.74M USD | −19.66M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
